CureVac N.V. (CVAC)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 3.2800 |
| Open | 3.2800 |
| Bid | 3.2400 x 100 |
| Ask | 3.3000 x 400 |
| Day's range | 3.2100 - 3.3600 |
| 52-week range | 2.2150 - 7.9600 |
| Volume | |
| Avg. volume | 801,450 |
| Market cap | 737.993M |
| Beta (5Y monthly) | 2.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3900 |
| Earnings date | 12 Nov 2024 - 18 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.05 |
ZacksGSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.
Simply Wall St.News Flash: 8 Analysts Think CureVac N.V. (NASDAQ:CVAC) Earnings Are Under Threat
Market forces rained on the parade of CureVac N.V. ( NASDAQ:CVAC ) shareholders today, when the analysts downgraded...
Simply Wall St.CureVac Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
CureVac ( NASDAQ:CVAC ) Second Quarter 2024 Results Key Financial Results Revenue: €14.4m (up 91% from 2Q 2023). Net...
© 2024 Yahoo. All rights reserved.